60. Aplastic anemia Clinical trials / Disease details

Clinical trials : 245 / Drugs : 318 - (DrugBank : 86) / Drug target genes : 44 - Drug target pathways : 166

17 trials found

diseases per page:

Showing 1 to 10 of 17 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05600426 (ClinicalTrials.gov)	January 25, 2023	20/10/2022	A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Ap ...	A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation With Immune Suppr ...	Severe Aplastic Anemia	Drug: cyclosporine;Procedure: Matched Unrelated Donor Hematopoetic Stem Cell Transplant;Drug: horse ...	Boston Children's Hospital	Center for International Blood and Marrow Transplant Research;National Institutes of Health (NIH);Na ...	Recruiting	0 Years	25 Years	All	234	Phase 3	United States
2	NCT05049668 (ClinicalTrials.gov)	October 2021	13/9/2021	RACE 2: a Long Term Follow-up of Patients Participating in the RACE Trial	Long-term Follow-up of Patients Participating in RACE: the Prospective Randomized Multicenter Study ...	Severe Aplastic Anemia	Drug: ATGAM plus CsA with or without Eltrombopag	European Society for Blood and Marrow Transplantation	NULL	Enrolling by invitation	N/A	N/A	All	197		France
3	NCT03025698 (ClinicalTrials.gov)	September 30, 2017	12/1/2017	A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Pre ...	A Phase II, Open-label, Non-controlled, Intra-patient Dose-escalation Study to Characterize the Phar ...	Aplastic Anemia	Drug: Eltrombopag;Drug: hATG;Drug: CsA	Novartis Pharmaceuticals	NULL	Active, not recruiting	1 Year	18 Years	All	51	Phase 2	United States;Hong Kong;Portugal;Russian Federation;Thailand;United Kingdom;Netherlands
4	NCT03413306 (ClinicalTrials.gov)	December 10, 2016	22/12/2017	Eltrombopag+hATG+CsA vs. hATG+CsA in Children With Severe AA	A Phase II Multicenter Randomized Study of Eltrombopag Combined With Cyclosporine and hATGVersus hAT ...	Acquired Aplastic Anemia	Drug: Eltrombopag;Drug: IST (ATG + CsA)	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	NULL	Recruiting	2 Years	18 Years	All	100	Phase 3	Russian Federation
5	NCT02845596 (ClinicalTrials.gov)	August 2016	9/5/2016	Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia	Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia	Severe Aplastic Anemia	Drug: cyclosporine;Procedure: Matched Unrelated Donor Hematopoietic Stem Cell Transplant;Drug: horse ...	Michael Pulsipher, MD	NULL	Active, not recruiting	N/A	25 Years	All	40	N/A	United States
6	EUCTR2014-000363-40-NL (EUCTR)	07/01/2016	01/09/2015	A trial in which will be studied if the addition of a medicine that is used for improving platelet c ...	A prospective Randomized multicenter study comparing horse Antithymocyte globuline (hATG) + Cyclospo ...	Idiopathic (Severe) Aplastic Anemia, a bone marrow failure syndrome which results in the normal hema ...	Trade Name: REVOLADE INN or Proposed INN: ELTROMBOPAG	European Society for Blood and Marrow Transplantation	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	200	Phase 3	Spain;Netherlands
7	EUCTR2014-000363-40-ES (EUCTR)	26/10/2015	07/09/2015	A trial in which will be studied if the addition of a medicine that is used for improving platelet c ...	A prospective Randomized multicenter study comparing horse Antithymocyte globuline (hATG) + Cyclospo ...	Idiopathic (Severe) Aplastic Anemia, a bone marrow failure syndrome which results in the normal hema ...	Trade Name: Revolade INN or Proposed INN: ELTROMBOPAG	European Society for Blood and Marrow Transplantation	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	200		Spain
8	NCT02462252 (ClinicalTrials.gov)	October 2015	25/5/2015	Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclospori ...	A Phase IIA, Open-label Study Designed to Evaluate Efficacy and Safety of BL-8040 Followed by Anti-T ...	Aplastic Anemia;Hypoplastic Myelodysplastic Syndrome	Drug: BL-8040;Drug: horse anti-thymocyte globulin (hATG);Drug: Methylprednisolone;Drug: Cyclosporine	BioLineRx, Ltd.	NULL	Recruiting	18 Years	N/A	All	25	Phase 2	United States
9	NCT02099747 (ClinicalTrials.gov)	July 2015	6/3/2014	hATG+CsA vs hATG+CsA+Eltrombopag for SAA	A Prospective Randomized Multicenter Study Comparing Horse Antithymocyte Globuline (hATG) + Cyclospo ...	Severe Aplastic Anemia	Drug: hATG;Drug: CsA;Drug: Eltrombopag	European Group for Blood and Marrow Transplantation	Novartis;Pfizer	Active, not recruiting	15 Years	N/A	All	202	Phase 3	France;Italy;Netherlands;Spain;Switzerland;United Kingdom;Germany
10	NCT01623167 (ClinicalTrials.gov)	July 2, 2012	14/6/2012	Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia	Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia	Severe Aplastic Anemia	Drug: Cohort 1: hATG, CsA, EPAG Day 14 to Month 6;Drug: Cohort 2: hATG, CsA, EPAG Day 14 to Month 3; ...	National Heart, Lung, and Blood Institute (NHLBI)	Novartis	Recruiting	2 Years	95 Years	All	207	Phase 1/Phase 2	United States

First Previous1 2Next Last